Drug Information

Drug General Information
Drug ID
D09VBE
Former ID
DNCL001873
Drug Name
Elinogrel
Drug Type
Small molecular drug
Indication Myocardial infarction [ICD9: 410; ICD10:I21, I22] Phase 1 [522795]
Company
Novartis Pharmaceuticals; Portola Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C20H15ClFN5O5S2
Canonical SMILES
CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)<br />(=O)C4=CC=C(S4)Cl)F
InChI
1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)
InChIKey
LGSDFTPAICUONK-UHFFFAOYSA-N
CAS Number
CAS 936500-94-6
PubChem Compound ID
16066663
PubChem Substance ID
24708235, 28683931, 29951121, 124490347, 125569866, 135261557, 137128526, 137213117, 139704826, 160708506, 163346228, 180371715, 198951229, 223685683, 226523885, 245943718, 249896062, 252158770, 252215341
Target and Pathway
Target(s) P2Y purinoceptor 12 Target Info Antagonist [530744]
KEGG Pathway Platelet activation
Reactome P2Y receptors
G alpha (i) signalling events
WikiPathways GPCRs, Class A Rhodopsin-like
Signal amplification
GPCR ligand binding
GPCR downstream signaling
References
Ref 522795ClinicalTrials.gov (NCT00984113) Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment. U.S. National Institutes of Health.
Ref 530744Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.